Profile data is unavailable for this security.
About the company
Cardiol Therapeutics Inc. is a Canada-based clinical-stage life sciences company focused on developing anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease. The Company's lead small-molecule drug candidate, CardiolRx (cannabidiol) oral solution, is pharmaceutically manufactured and in clinical development for use in the treatment of heart disease. It holds investigational new drug application authorization from the United States Food and Drug Administration (US FDA) to conduct clinical studies to evaluate the efficacy and safety of CardiolRx in two diseases affecting the heart: recurrent pericarditis and acute myocarditis. The MAVERIC Program in recurrent pericarditis, an inflammatory disease, comprises the completed Phase II MAvERIC-Pilot study (NCT05494788) and the ongoing Phase III MAVERIC trial (NCT06708299). The Company is also developing CRD-38, a novel subcutaneously administered drug formulation intended for use in heart failure.
- Revenue in CAD (TTM)0.00
- Net income in CAD-34.78m
- Incorporated2017
- Employees18.00
- LocationCardiol Therapeutics Inc602-2265 Upper Middle Road EastOAKVILLE L6H 0G5CanadaCAN
- Phone+1 (289) 910-0850
- Fax+1 (905) 491-6793
- Websitehttps://www.cardiolrx.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gain Therapeutics Inc | 0.00 | -26.52m | 142.55m | 23.00 | -- | 16.50 | -- | -- | -0.6364 | -0.6364 | 0.00 | 0.1643 | 0.00 | -- | -- | 0.00 | -153.07 | -79.58 | -234.03 | -95.32 | -- | -- | -- | -19,975.78 | -- | -33.79 | 0.067 | -- | -100.00 | -- | 8.34 | -- | 10.39 | -- |
| Turn Therapeutics Inc | -136.76bn | -136.76bn | 147.39m | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| Korro Bio Inc | 10.08m | -120.92m | 148.11m | 87.00 | -- | 1.09 | -- | 14.69 | -9.42 | -9.42 | 0.7855 | 10.54 | 0.0364 | -- | 1.36 | 70,875.00 | -43.65 | -- | -46.92 | -- | -- | -- | -1,199.53 | -- | -- | -- | 0.00 | -- | -- | -- | -2.97 | -- | -- | -- |
| Oncolytics Biotech Inc | 0.00 | -35.27m | 150.11m | 29.00 | -- | 1,257.10 | -- | -- | -0.2868 | -0.2868 | 0.00 | 0.0008 | 0.00 | -- | -- | -- | -179.40 | -75.50 | -293.88 | -87.03 | -- | -- | -- | -- | -- | -- | 0.879 | -- | -- | -- | -14.26 | -- | 85.40 | -- |
| Helix Biopharma Corp | 0.00 | -4.88m | 150.46m | 7.00 | -- | 9.37 | -- | -- | -0.0833 | -0.0833 | 0.00 | 0.2104 | 0.00 | -- | -- | -- | -50.07 | -166.45 | -66.34 | -430.79 | -- | -- | -- | -- | -- | -24.39 | 0.0214 | -- | -- | -- | 43.81 | -- | -34.02 | -- |
| Cassava Sciences Inc | 0.00 | -145.01m | 153.28m | 30.00 | -- | 1.37 | -- | -- | -2.20 | -2.20 | 0.00 | 1.69 | 0.00 | -- | -- | 0.00 | -59.99 | -28.22 | -85.37 | -29.72 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 74.96 | -- | 41.75 | -- |
| ALX Oncology Holdings Inc | 0.00 | -147.72m | 157.20m | 44.00 | -- | 2.54 | -- | -- | -2.01 | -2.01 | 0.00 | 0.8362 | 0.00 | -- | -- | 0.00 | -80.47 | -37.96 | -103.67 | -40.71 | -- | -- | -- | -46,390.86 | -- | -- | 0.2099 | -- | -- | -- | 16.14 | -- | 4.84 | -- |
| Coya Therapeutics Inc | 5.45m | -25.21m | 157.45m | 8.00 | -- | 3.01 | -- | 28.87 | -1.11 | -1.11 | 0.2397 | 1.63 | 0.118 | -- | -- | 498,462.50 | -54.54 | -- | -59.84 | -- | -- | -- | -462.26 | -- | -- | -- | 0.00 | -- | -40.79 | -- | -86.29 | -- | -- | -- |
| Cardiol Therapeutics Inc | 0.00 | -34.78m | 157.56m | 18.00 | -- | 12.90 | -- | -- | -0.4207 | -0.4207 | 0.00 | 0.1093 | 0.00 | -- | -- | 0.00 | -228.34 | -65.44 | -344.00 | -77.84 | -- | -- | -- | -187,932.20 | -- | -- | 0.0138 | -- | -- | -- | -30.39 | -- | -45.03 | -- |
| Equillium Inc | 6.01m | -33.39m | 159.90m | 35.00 | -- | 3.77 | -- | 26.62 | -0.632 | -0.632 | 0.1021 | 0.5099 | 0.1274 | -- | 1.71 | 125,485.70 | -70.81 | -44.86 | -89.09 | -58.85 | -- | -- | -555.94 | -164.30 | -- | -- | 0.00 | -- | 13.89 | -- | 39.51 | -- | 2.81 | -- |
| Aardvark Therapeutics Inc | 0.00 | -66.70m | 162.89m | 33.00 | -- | 0.972 | -- | -- | -2.53 | -2.53 | 0.00 | 5.63 | 0.00 | -- | -- | -- | -44.96 | -- | -47.90 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -185.63 | -- | -- | -- |
| Inovio Pharmaceuticals Inc | 249.36k | -147.83m | 163.49m | 134.00 | -- | -- | -- | 655.65 | -2.63 | -2.63 | 0.0046 | -0.1441 | 0.0021 | -- | 0.1283 | 1,360.67 | -122.52 | -58.57 | -260.08 | -70.33 | -- | -- | -59,283.97 | -4,810.90 | -- | -6.49 | -- | -- | -73.83 | -44.44 | 20.62 | -- | -13.16 | -- |
| Agenus Inc | 146.10m | -48.39m | 165.09m | 316.00 | -- | -- | -- | 1.13 | -2.09 | -2.09 | 3.94 | -8.35 | 0.4523 | -- | 286.79 | 338,066.50 | -16.63 | -58.29 | -- | -140.29 | 98.93 | 97.31 | -36.77 | -125.67 | -- | -1.17 | 6.78 | -- | -33.81 | -7.17 | 7.54 | -- | -34.16 | -- |
| Tenaya Therapeutics Inc | 0.00 | -128.91m | 166.63m | 97.00 | -- | 1.13 | -- | -- | -0.7875 | -0.7875 | 0.00 | 0.5061 | 0.00 | -- | -- | 0.00 | -76.77 | -47.44 | -87.21 | -51.82 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 10.44 | -- | -18.92 | -- |
| MacroGenics Inc | 174.55m | -103.79m | 167.84m | 341.00 | -- | 1.83 | -- | 0.9616 | -1.21 | -1.21 | 2.02 | 1.06 | 0.4769 | 5.23 | 3.27 | 374,266.90 | -28.36 | -33.40 | -35.18 | -40.60 | 75.41 | -- | -59.46 | -97.17 | 5.02 | -26.97 | 0.5119 | -- | 155.26 | 18.50 | -639.30 | -- | -2.88 | -- |
| Spero Therapeutics Inc | 55.46m | -59.95m | 168.74m | 32.00 | -- | 4.65 | -- | 3.04 | -0.7949 | -0.7949 | 0.7299 | 0.4705 | 0.4283 | -- | 1.45 | 1,267,156.00 | -46.31 | -35.16 | -69.26 | -42.63 | -- | -- | -108.11 | -111.75 | -- | -- | 0.00 | -- | -53.77 | 21.46 | -400.65 | -- | -- | -- |
Data as of Mar 02 2026. Currency figures normalised to Cardiol Therapeutics Inc's reporting currency: Canadian Dollar CAD
20.64%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| MM Asset Management, Inc.as of 31 Jan 2026 | 11.97m | 11.97% |
| Tejara Capital Ltd.as of 17 Oct 2025 | 5.13m | 5.13% |
| Global X Investments Canada, Inc.as of 31 Jan 2026 | 882.00k | 0.88% |
| AdvisorShares Investments LLCas of 31 Dec 2025 | 597.98k | 0.60% |
| Integrity Alliance LLC (US)as of 31 Dec 2025 | 435.03k | 0.44% |
| Two Sigma Investments LPas of 31 Dec 2025 | 406.94k | 0.41% |
| Merrill Lynch Canada, Inc.as of 31 Dec 2025 | 363.45k | 0.36% |
| Goldman Sachs & Co. LLC (Private Banking)as of 31 Dec 2025 | 328.50k | 0.33% |
| Morgan Stanley & Co. LLCas of 31 Dec 2025 | 327.95k | 0.33% |
| Susquehanna Financial Group LLLPas of 31 Dec 2025 | 203.73k | 0.20% |
More ▼
Data from 31 Dec 2025 - 26 Feb 2026Source: FactSet Research Systems Inc.
